Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06810544 is registered in ClinicalTrials.gov with Tango Therapeutics, Inc. as lead sponsor.

NCT NCT06810544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Lead sponsor
Tango Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 24, 2025
Completion date
September 30, 2027
Enrollment
191 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, glioma glioblastoma multiforme, glioma, malignant, lung cancer, non small cell lung cancer, non-small cell adenocarcinoma, solid tumor